Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). (2022)
Attributed to:
Mathematical and Statistical Modelling to Optimise Paediatric Medicines Research
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13063-022-06533-0
PubMed Identifier: 35869526
Publication URI: http://europepmc.org/abstract/MED/35869526
Type: Journal Article/Review
Volume: 23
Parent Publication: Trials
Issue: 1
ISSN: 1745-6215